GLP-1 Receptor Agonists and Glaucoma: Exploring a Possible Association

By 
Dr Amit Kumar Singh
 on 
Dec 10, 2025
 • 
5
 min read

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide (Wegovy) and liraglutide, are transforming the management of type 2 diabetes mellitus (T2DM) and obesity. Everyone is well-versed in their effects on blood sugar, weight, and the cardiovascular system.

One area of growing clinical interest is the impact of GLP-1 RAs on eye health, specifically their relationship with glaucoma, a progressive optic neuropathy that can lead to irreversible vision loss.

According to the National Health Service (NHS), glaucoma is a significant public health concern, with chronic open-angle glaucoma affecting approximately 480,000 people across the country.

Recent research supported by large-scale retrospective studies suggests that GLP-1 RAs are associated with a reduced risk of glaucoma incidence, particularly primary open-angle glaucoma (POAG), compared with other antidiabetic agents. This article provides a comprehensive, evidence-based analysis of the current state of knowledge regarding GLP-1 RAs and glaucoma risk.

GLP-1 RAs and Glaucoma

GLP-1 RAs, also known as incretin mimetics, are a class of drugs that enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, making them effective treatments for T2DM and obesity. Semaglutide, in particular, has gained widespread attention due to its efficacy in both glycaemic control and weight reduction.

Glaucoma is an umbrella term for a group of optic neuropathies characterised by progressive loss of retinal ganglion cells (RGCs) and corresponding visual field defects, frequently but not exclusively associated with elevated intraocular pressure (IOP). The most common subtype, primary open-angle glaucoma (POAG), is a leading cause of irreversible blindness worldwide. Diabetes is a well-recognised risk factor for glaucoma, likely due to shared pathways involving vascular dysregulation, oxidative stress, and neurodegeneration.

The Current Clinical Evidence

Several robust observational studies have investigated the association between GLP-1 RA use and glaucoma risk. Population-based registry analyses from Denmark and large US cohort studies consistently demonstrate a protective signal. Research, like a Danish nationwide case control study, found that patients with T2DM initiating GLP-1 RA therapy had a 19–29% lower risk of developing POAG compared to those prescribed other anti-diabetic agents. These findings further suggest that the magnitude of risk reduction increases with the duration of GLP-1 RA exposure; patients using these agents for more than three years experienced the most pronounced benefits.

Importantly, emerging data indicate that the glaucoma-protective effect of GLP-1 RAs may extend beyond patients with diabetes. Observational analyses in obese, non-diabetic individuals prescribed GLP-1 RAs for weight management also show a reduced risk of incident glaucoma.

This suggests the benefit may not solely be attributabled to improved glycaemic control and may instead reflect a direct neuroprotective action. While these findings are compelling, it is crucial to acknowledge the limitations inherent in observational research, including residual confounding and potential selection bias.

Nevertheless, the consistency and magnitude of the association, alongside plausible biological mechanisms, strengthen the case for a genuine effect.

How GLP-1s Protect the Eye?

The mechanisms underlying the glaucoma-protective effects of GLP-1 RAs are under active investigation. The following pathways are most frequently proposed:

  • Neuroprotection: GLP-1 receptors are expressed on retinal ganglion cells (RGCs), the primary targets in glaucoma. Agonism of these receptors may inhibit RGC apoptosis by modulating intracellular signalling pathways, enhancing cell survival, and reducing excitotoxicity. This is consistent with broader neuroprotective paradigms observed in stroke and neurodegeneration, where targeting multi-modal pathways (including inflammatory and apoptotic cascades) can yield meaningful protection.
  • Anti-Inflammatory Action: GLP-1 RAs exert systemic and tissue-specific anti-inflammatory effects. In the eye, they may dampen microglial activation and inhibit the release of pro-inflammatory cytokines, reducing oxidative stress and interrupting the inflammatory cycles that drive glaucomatous damage.
  • IOP Modulation (The Hypothesis): Some preclinical studies suggest that GLP-1 RAs may influence aqueous humour dynamics, potentially lowering IOP, although this effect appears less robust than their neuroprotective actions. The overall reduction in glaucoma risk observed in non-glaucomatous, normotensive populations supports the idea of a pressure-independent mechanism.

Collectively, these mechanisms align with contemporary theories of glaucoma pathogenesis as a neurodegenerative disease with vascular and inflammatory components, not simply one of elevated IOP.

Ocular Risks to be Vigilant About

While the evidence for a glaucoma-protective effect is encouraging, clinicians should balance this against specific ocular safety considerations associated with GLP-1 RAs. These include the potential for diabetic retinopathy progression and the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Diabetic Retinopathy (DR) Progression

A paradox exists in the relationship among GLP-1 RAs, glycaemic control, and progression of diabetic retinopathy (DR). Long-term glycaemic improvement is unequivocally beneficial for retinopathy risk, yet rapid reductions in glycated haemoglobin (HbA​1c​​), particularly greater than 2% over a short period, can transiently worsen pre-existing, advanced DR. This phenomenon was highlighted in the SUSTAIN-6 trial, where patients with advanced baseline DR who experienced rapid HbA​1c​​ declines on semaglutide had higher rates of retinopathy progression compared to controls.

Key clinical implications include:

  • Baseline eye examination is essential before or shortly after initiating GLP-1 RA therapy, particularly in patients with advanced DR.
  • Gradual titration and individualised glycaemic targets may mitigate the risk of rapid retinopathy progression.
  • Ongoing surveillance is recommended, especially during the first year of treatment.

This emphasises the need for careful patient selection and counselling, as well as integrated care between diabetologists, general practitioners, and ophthalmologists.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION is characterised by sudden, painless visual loss due to infarction of the optic nerve head in the absence of giant cell arteritis. While rare, several post-marketing reports and some large database studies suggest a possible increased risk of NAION associated with certain GLP-1 RAs, including semaglutide.

The proposed mechanism involves systemic fluctuations in blood pressure and glucose, which, when superimposed on a “disc at risk” (an anatomically crowded optic nerve head), may precipitate ischemic events. Patients with diabetes, hypertension, hyperlipidaemia, and established small vessel disease are particularly susceptible.

Clinical recommendations include:

  • Screening for NAION risk factors before and during GLP-1 RA therapy.
  • Prompt evaluation of any new, sudden visual symptoms.
  • Patient education regarding the signs and symptoms of NAION.

Mechanistic Parallels: Neuroprotection Beyond the Eye

The neuroprotective properties of GLP-1 RAs in glaucoma reflect a broader paradigm shift in the management of neurodegenerative diseases, emphasising multi-modal strategies that target not only acute injury but also the chronic processes underpinning neuronal loss. Lessons from preclinical and translational research in cerebral ischemia and stroke illuminate both the promise and challenges of neuroprotective therapy.

Amato and Arnold (2020) provided additional mechanistic clarity, modelling the activation of microglia and the balance between pro- and anti-inflammatory phenotypes (M1 and M2) in ischemic stroke. Their results suggest that early inhibition of M1 (pro-inflammatory) activation and support of M2 (anti-inflammatory) activation can shift the neuroinflammatory milieu towards tissue repair and recovery. By extension, GLP-1 RAs through their modulation of microglial activation may replicate these neuroprotective dynamics in the optic nerve, offering a biological rationale for the observed reduction in glaucoma risk.

Conclusion

Current research has examined a possible association between GLP-1 receptor agonist use and glaucoma-related outcomes, but the evidence remains limited and observational. Proposed neurobiological mechanisms have not been conclusively established, and no protective effect has been confirmed.

Existing literature highlights the importance of clinical awareness of ocular changes, particularly in people with diabetes, including transient changes in diabetic retinopathy and rare optic nerve events. Clinical decisions should continue to follow approved indications, individual patient factors, and established guidelines.

Further prospective and randomised studies are needed to clarify any relationship between GLP-1 receptor agonists and glaucoma, as well as their long-term ocular safety.

References

  1. Amato S, Arnold A. Modelling Microglia Activation and Inflammation-Based Neuroprotectant Strategies During Ischemic Stroke. Bull Math Biol. 2021 May 12;83(6):72. doi: 10.1007/s11538-021-00905-4. PMID: 33982158. https://pubmed.ncbi.nlm.nih.gov/33982158/ 
  2. Niazi, Siar et al.Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes. Ophthalmology, Volume 131, Issue 9, 1056 - 1063https://www.aaojournal.org/article/S0161-6420(24)00171
  3. NHS UK Glaucoma Prevalence Statistics NHS. (2023, October 13). Glaucoma.https://www.nhs.uk/conditions/glaucoma/
  4. Amaral DC, Guedes J, Cruz MRB, Cheidde L, Nepomuceno M, Magalhães PLM, Brazuna R, Mora-Paez DJ, Huang P, Razeghinejad R, Schuman JS, Myers JS. GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025 Mar;271:488-497. doi: 10.1016/j.ajo.2024.12.024. Epub 2024 Dec 27. PMID: 39732312.https://pubmed.ncbi.nlm.nih.gov/39732312/
Take charge of how you look and feel.
Backed by science. Guided by experts.

SheMed’s medical weight loss programme combines expert care and science-backed treatment to help you feel and look your best — for life.
The content on the SheMed blog is provided for general informational and educational purposes only. While SheMed provides professional weight loss services and strives to ensure the information shared is accurate and up to date, we make no representations or guarantees as to its accuracy, completeness, or timeliness. This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider. Always speak with your doctor or licensed medical professional about your individual health or medical needs before starting any new treatment or programme. Never disregard or delay seeking professional medical advice because of something you have read on this site.  SheMed is not responsible for any actions you may take based on the information provided in this blog.

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.